Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Arexvy single-dose RSV vaccination and different revaccination schedules in adults aged 60 years and older
2024-512291-34-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV), sponsored by GSK. Primary endpoint: Neutralizing antibody response against RSV-A and RSV-B through Month 12. Planned start Feb 2021; status: authorised.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-512291-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512291-34-00.